Cargando…
Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway
Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death. Most (75–85%) primary liver cancers occurring worldwide are hepatocellular carcinoma (HCC). The development of resistance and other drug related side effects are the prime reasons for the failure o...
Autores principales: | Hu, Xue, Jiao, Fangzhou, Zhang, Lan, Jiang, Yingan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117156/ https://www.ncbi.nlm.nih.gov/pubmed/33995073 http://dx.doi.org/10.3389/fphar.2021.654986 |
Ejemplares similares
-
Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway
por: Wang, Linjun, et al.
Publicado: (2023) -
Dihydrotanshinone I Specifically Inhibits NLRP3 Inflammasome Activation and Protects Against Septic Shock In Vivo
por: Wei, Ziying, et al.
Publicado: (2021) -
Enhanced Bioavailability of Dihydrotanshinone I–Bovine Serum Albumin Nanoparticles for Stroke Therapy
por: Ren, Yanru, et al.
Publicado: (2021) -
STAT3-mediated activation of mitochondrial pathway contributes to antitumor effect of dihydrotanshinone I in esophageal squamous cell carcinoma cells
por: Qi, Ming-Ming, et al.
Publicado: (2021) -
Taxus wallichiana var. chinensis (Pilg.) Florin Aqueous Extract Suppresses the Proliferation and Metastasis in Lung Carcinoma via JAK/STAT3 Signaling Pathway
por: Sun, Leitao, et al.
Publicado: (2021)